Study Summary
This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell Malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Allogeneic hematological stem cell transplantationPROCEDURE
Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | China |